Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-01-08
The beginning of the end for Type I diabetes: A new view from immunotherapy science
2020-09-07
Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer
2020-07-28
Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study
2020-03-04
Imcyse Joins Type 1 Diabetes IMI Consortium INNODIA
2019-09-18
Imcyse to present first-in-human phase 1B study results in Type 1 diabetes at EASD 2019

©imcyse 2023